Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.50 |
| ▸ | FDPS | P14324 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050718 | 0.92 | ALOX15 (0.57) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| SCHEMBL991834 | 0.92 | ALOX15 (0.57) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| SCHEMBL4608511 | 0.83 | ALOX15 (0.57) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| SCHEMBL5136231 | 0.83 | ALOX15 (0.57) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| Citronellic Acid SCHEMBL29908535 | 0.82 | GGPS1 (0.52) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| Citronellic Acid SCHEMBL29715943 | 0.82 | ALOX15 (0.52) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| SCHEMBL3879795 | 0.82 | ALOX15 (0.47) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| Citronellic Acid SCHEMBL714852 | 0.82 | ALOX15 (0.55) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| Citronellic Acid SCHEMBL193354 | 0.82 | ALOX15 (0.55) | ALOX15ALDH1A1GGPS1FDPSTSHR | |
| Citronellic Acid SCHEMBL712982 | 0.82 | ALOX15 (0.55) | ALOX15ALDH1A1GGPS1FDPSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012097-B2 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2006-03-14 | — | — | US | claimed |
| US-20030219847-A1 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION | 2003-11-27 | — | — | US | claimed |
| WO-2000033826-A1 | ANTICANCER AGENTS BASED ON PREVENTION OF PROTEIN PRENYLATION | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2000-06-15 | — | — | WO | claimed |
| US-7344851-B2 | Anticancer agents based on prevention of protein prenylation | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2008-03-18 | — | — | US | disclosed |
| US-7344851-B2 | Anticancer agents based on prevention of protein prenylation | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2008-03-18 | — | — | US | disclosed |
| US-7344851-B2 | Anticancer agents based on prevention of protein prenylation | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2008-03-18 | — | — | US | disclosed |
| US-7012097-B2 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2006-03-14 | — | — | US | disclosed |
| US-20060030624-A1 | Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase; drug screening; antitumor agents; antiproliferative agents | ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2006-02-09 | — | — | US | disclosed |
| US-20030219847-A1 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION | 2003-11-27 | — | — | US | disclosed |
| US-6576436-B1 | Inactivating farnesyltransferase using a alpha-dicarbonyl compound of given formula; drug screening; antitumor agents; antiproliferative agents | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION | 2003-06-10 | — | — | US | disclosed |
| WO-2000033826-A1 | ANTICANCER AGENTS BASED ON PREVENTION OF PROTEIN PRENYLATION | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219847-A1 | Anticancer agents based on prevention of protein prenylation | RCE1, FNTA, FNTB | ALOX15 3659/4885ALDH1A1 2526/4885GGPS1 4/4885 |
| US-20060030624-A1 | Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase; drug screening; antitumor agents; antiproliferative agents | FNTA, FNTB, RCE1 | ALOX15 4243/4885ALDH1A1 1179/4885GGPS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.